3 Registrar and Transfer Agent, Truck Suspension Springs Maker and Finished Dosage Generics Maker Stocks With a Strong Future Roadmap: KFin Technologies, Jamna Auto Industries and Strides Pharma Science
- November 4, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
KFin Technologies, Jamna Auto Industries and Strides Pharma Science: ROE of 17.9% to 20.5% and FY22 to FY26 revenue CAGR of 11.1% to 20.1%. Prices as of 3 Nov 2026.
Quick Answer
The three registrar, truck spring and generic drug stocks to watch are KFin Technologies, Jamna Auto Industries and Strides Pharma Science. Their return on equity ranges from 17.9% to 20.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.1% to 20.1%. KFin Technologies leads on both return on equity at 20.5% and revenue growth at 20.1% a year. Prices are based on the 3 November 2026 close, and this article is educational, not investment advice.
Registrar, truck spring and generic drug stocks bring together companies with a visible plan for the years ahead. KFin Technologies, Jamna Auto Industries and Strides Pharma Science cover a registrar and transfer agent, a truck suspension springs maker and a finished dosage generics maker.
This list covers three registrar, truck spring and generic drug stocks with complete current figures: KFin Technologies, Jamna Auto Industries and Strides Pharma Science. Every figure comes from the latest reported financials and the 3 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Registrar, Truck Spring and Generic Drug Stocks?
Registrar, truck spring and generic drug stocks are listed companies that serve mutual funds and issuers as a registrar, make leaf and parabolic springs for trucks, trailers and buses, and produce finished dosage generics for regulated markets. Their earnings depend on fund and issuer activity, commercial vehicle output and export approvals.
Registrar, Truck Spring and Generic Drug Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| KFin Technologies | 861.6 | 15,062 | 44.1 | 41.8 | 20.5 | 0.03 |
| Jamna Auto Industries | 122.98 | 5,570 | 23.8 | 36.9 | 20.1 | 0.01 |
| Strides Pharma Science | 1,037.3 | 9,491 | 15.0 | 36.0 | 17.9 | 0.57 |
On valuation, Jamna Auto Industries and Strides Pharma Science trade at a P/E below the industry P/E, while KFin Technologies trades above it, which reflects the growth the market already expects. Readers comparing registrar, truck spring and generic drug stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in registrar, truck spring and generic drug stocks can use the coming numbers to test whether growth is holding.
Why Do Registrar, Truck Spring and Generic Drug Stocks Have a Strong Roadmap in India?
Registrar, truck spring and generic drug stocks have a strong roadmap in India because growing investor participation, rising freight vehicle output and steady demand for generics keep widening the market for these companies.
- Registrar services. More investors mean more fund and issuer work.
- Suspension springs. Trucks and buses need strong springs.
- Generics. Regulated markets buy dependable supply.
Why KFin Technologies Features Among These Registrar, Truck Spring and Generic Drug Stocks
Among the registrar, truck spring and generic drug stocks on this list, KFin Technologies is a registrar and transfer agent that serves mutual funds, corporate issuers and pension and alternative investment clients in India and overseas.
In the June 2026 quarter, revenue grew 29.1% year on year to Rs 367 crore. Revenue rose from Rs 646 crore in FY22 to Rs 1,344 crore in FY26, a compound annual growth rate of 20.1%.
Net profit grew from Rs 149 crore in FY22 to Rs 344 crore in FY26, which works out to a compound annual growth rate of 23.3%. The company has a return on equity of 20.5%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 15,062 crore. The stock trades at a P/E of 44.1, above the industry P/E of 41.8.
Roadmap: Its growth comes from mutual fund assets, corporate registry work, and a rising international presence, including offshore fund administration. Diversified services reduce reliance on any one client category.
What to watch: Monitor mutual fund industry growth and new international client wins.
Why Jamna Auto Industries Features Among These Registrar, Truck Spring and Generic Drug Stocks
Among the registry and truck part shares on this list, Jamna Auto Industries makes leaf and parabolic springs for commercial vehicles, trailers and buses, and holds a leading position in India’s suspension springs.
The company has a return on equity of 20.1%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 5,570 crore. The stock trades at a P/E of 23.8, below the industry P/E of 36.9.
Revenue rose from Rs 1,723 crore in FY22 to Rs 2,621 crore in FY26, a compound annual growth rate of 11.1%. Net profit grew from Rs 141 crore in FY22 to Rs 231 crore in FY26, which works out to a compound annual growth rate of 13.2%. In the June 2026 quarter, revenue grew 6.8% year on year to Rs 614 crore, while net profit rose 6.1% to Rs 48.5 crore.
Roadmap: The company benefits from replacement demand and from the shift to lighter, parabolic springs that carry higher margins. A fleet upgrade cycle and infrastructure spending drive commercial vehicle volumes, and Jamna also sells to the aftermarket.
What to watch: Monitor commercial vehicle production trends and steel price movements.
Why Strides Pharma Science Features Among These Registrar, Truck Spring and Generic Drug Stocks
Among the three companies on this list, Strides Pharma Science, based in Bengaluru, makes finished dosage generics for the United States and other regulated markets, with oral solids and soft gel capsules as important product groups.
Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%.
In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0.
Roadmap: The company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
What to watch: Track new US launches and the pace of price erosion in generic categories.
KFin Technologies vs Jamna Auto Industries vs Strides Pharma Science on Key Financials
The table below sets the three registrar, truck spring and generic drug stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| KFin Technologies | 646 | 1,344 | 20.1% | 344 | 25.6% |
| Jamna Auto Industries | 1,723 | 2,621 | 11.1% | 231 | 8.8% |
| Strides Pharma Science | 3,202 | 5,009 | 11.8% | 575 | 11.5% |
KFin Technologies posts the highest return on equity in this group at 20.5%. Strides Pharma Science has the largest FY26 revenue at Rs 5,009 crore, and KFin Technologies shows the fastest revenue growth with a 20.1% compound annual rate. A useful habit with registrar, truck spring and generic drug stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several share registry, suspension and generic drug stocks instead of one name, which keeps a single result from deciding the outcome.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| KFin Technologies | 284 | 367 | 29.1% |
| Jamna Auto Industries | 575 | 614 | 6.8% |
| Strides Pharma Science | 1,128 | 1,270 | 12.6% |
Key Risks to Check Before Investing in Registrar, Truck Spring and Generic Drug Stocks
Every theme carries risks that deserve a check before any decision. For these registrar, truck spring and generic drug stocks, the main points are: Long-term registry and truck part shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Market activity. Fee income follows trading volumes and investor participation.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter registrar, truck spring and generic drug stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Registrar, Truck Spring and Generic Drug Stocks
Registrar, truck spring and generic drug stocks suit investors who prefer to study business strength before price moves. KFin Technologies, Jamna Auto Industries and Strides Pharma Science each have a clear plan to grow. Based on the 3 November 2026 close, KFin Technologies trades at Rs 861.6, Jamna Auto Industries at Rs 122.98 and Strides Pharma Science at Rs 1,037.3. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these registrar, truck spring and generic drug stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track registrar, truck spring and generic drug stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are registrar, truck spring and generic drug stocks?
Ans. Registrar, truck spring and generic drug stocks are listed companies that serve mutual funds and issuers as a registrar, make leaf and parabolic springs for trucks, trailers and buses, and produce finished dosage generics for regulated markets. Their earnings depend on fund and issuer activity, commercial vehicle output and export approvals. This list looks at three of them, KFin Technologies, Jamna Auto Industries and Strides Pharma Science, using reported FY22 to FY26 financials and the 3 November 2026 closing prices.
Which registrar, truck spring and generic drug stocks are covered in this list?
Ans. This list covers KFin Technologies, Jamna Auto Industries and Strides Pharma Science. Based on the 3 November 2026 close, KFin Technologies traded at Rs 861.6, Jamna Auto Industries at Rs 122.98 and Strides Pharma Science at Rs 1,037.3. Their return on equity ranges from 17.9% to 20.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.1% to 20.1%.
Why do registrar, truck spring and generic drug stocks have a strong future roadmap in India?
Ans. Registrar, truck spring and generic drug stocks have a strong roadmap in India because growing investor participation, rising freight vehicle output and steady demand for generics keep widening the market for these companies. The main drivers are as follows. Registrar services. More investors mean more fund and issuer work. Suspension springs. Trucks and buses need strong springs. Generics. Regulated markets buy dependable supply. Together these factors give the companies on this list a visible path for growth over the coming years.
How has KFin Technologies performed financially?
Ans. Revenue rose from Rs 646 crore in FY22 to Rs 1,344 crore in FY26, a compound annual growth rate of 20.1%. Net profit grew from Rs 149 crore in FY22 to Rs 344 crore in FY26, which works out to a compound annual growth rate of 23.3%. In the June 2026 quarter, revenue grew 29.1% year on year to Rs 367 crore. The company has a return on equity of 20.5%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 15,062 crore. The stock trades at a P/E of 44.1, above the industry P/E of 41.8. Looking ahead, its growth comes from mutual fund assets, corporate registry work, and a rising international presence, including offshore fund administration. Diversified services reduce reliance on any one client category.
How has Jamna Auto Industries performed financially?
Ans. Revenue rose from Rs 1,723 crore in FY22 to Rs 2,621 crore in FY26, a compound annual growth rate of 11.1%. Net profit grew from Rs 141 crore in FY22 to Rs 231 crore in FY26, which works out to a compound annual growth rate of 13.2%. In the June 2026 quarter, revenue grew 6.8% year on year to Rs 614 crore, while net profit rose 6.1% to Rs 48.5 crore. The company has a return on equity of 20.1%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 5,570 crore. The stock trades at a P/E of 23.8, below the industry P/E of 36.9. Looking ahead, the company benefits from replacement demand and from the shift to lighter, parabolic springs that carry higher margins. A fleet upgrade cycle and infrastructure spending drive commercial vehicle volumes, and Jamna also sells to the aftermarket.
How has Strides Pharma Science performed financially?
Ans. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
What risks should investors check before buying registrar, truck spring and generic drug stocks?
Ans. Investors should check a few risks before buying registrar, truck spring and generic drug stocks. Market activity. Fee income follows trading volumes and investor participation. Regulatory approvals. Plant inspections and approvals can affect supplies. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of registrar, truck spring and generic drug stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 3 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
